Medications for Hormone Refractory Prostate Cancer

6 results

  • lynparza - olaparib tablet, film coated

    (Olaparib)
    Astrazeneca Pharmaceuticals Lp
    Lynparza is a PARP inhibitor for adults with BRCA- or HRR-mutated cancers. Indicated for maintenance of ovarian cancer, adjuvant and metastatic breast cancer, maintenance of metastatic pancreatic cancer, and metastatic castration-resistant prostate cancer. Patient selection requires an FDA-approved companion diagnostic.
    Medication Details
    Drug Interactions

  • nubeqa - darolutamide tablet, film coated

    (Darolutamide)
    Bayer Healthcare Pharmaceuticals Inc.
    NUBEQA is an androgen receptor inhibitor for adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic castration-sensitive prostate cancer (mCSPC), including mCSPC in combination with docetaxel.
    Medication Details
    Drug Interactions

  • provenge

    (Sipuleucel-T)
    Dendreon Pharmaceuticals Llc
    Provenge (sipuleucel-T) is an autologous cellular immunotherapy for asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.
    Medication Details
    Drug Interactions

  • talzenna - talazoparib capsule, liquid filled

    (Talazoparib)
    Pfizer Laboratories Div Pfizer Inc
    Talzenna treats adults with gBRCAm HER2-negative locally advanced or metastatic breast cancer as a single agent, and in combination with enzalutamide for adults with HRR gene-mutated metastatic castration-resistant prostate cancer.
    Medication Details
    Savings Programs
    1
    Drug Interactions

  • xofigo - radium ra 223 dichloride injection

    (Radium Ra 223 Dichloride)
    Bayer Healthcare Pharmaceuticals Inc.
    Xofigo treats castration-resistant prostate cancer in adults with symptomatic bone metastases and no known visceral metastatic disease.
    Medication Details
    Drug Interactions

  • xtandi - enzalutamide capsule

    (Enzalutamide)
    Astellas Pharma Us, Inc.
    Xtandi treats castration-resistant prostate cancer (CRPC), metastatic castration-sensitive prostate cancer (mCSPC), and non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence.
    Medication Details
    Savings Programs
    1
    Drug Interactions